These results suggest that the Mediumpurple2 network is downstream of striatal dopamine receptors and is sensitive to the treatment of dopaminergic agents, although the dopaminergic signaling cascades that regulate this network in the striatal Drd1+ and Drd2+ MSNs may be differentially perturbed by PD-like pathology. Here, DRD2 is linked to Parkinson disease.